tbuckley/cabot-search huggingface dataset:
Oxidative Metabolism in Fetal Rat Brain during Maternal Halothane Anesthesia
Authors: Robert C. Vannucci, Joan W. Wolf
Journal: Environmental Health Perspectives (1977)

The present study examines the effects of maternally administered halothane on fetal brain metabolism as determined by direct tissue analysis. Term pregnant rats were paralyzed, ventilated, and administered halothane in concentrations of 0.4, 1, or 2%. For comparison of fetal response to anesthetic agents, other maternal rats were administered pentobarbital (50 or 200 mg/kg). Dams receiving 0.4% halothane or 50 mg/kg pentobarbital remained normotensive, whereas 2% halothane or 200 mg/kg pentobarbital led to a 65% reduction in maternal blood pressure and a 3-fold increase in blood lactate. Fetal blood lactate tended to parallel the maternal lactacidemia. Fetuses of dams anesthetized with 0.4% halothane or 50 mg/kg pentobarbital exhibited concentrations of cerebral metabolities comparable to those of control animals. A 2% halothane level was associated with metabolic disturbances in fetal brain, indicative of cerebral hypoxia. Pentobarbital 200 mg/kg, although producing maternal hypotension and lactacidemia to a degree similar to 2% halothane, preserved a more optimal fetal cerebral energy state as reflected in a lower lactate/pyruvate ratio and normal ATP. The metabolic influence of pentobarbital may serve to protect the hypoxic fetus from neurological damage, an effect apparently not shared by maternally administered halothane.
A 34-year-old woman with persistent cough and diarrhea
Authors: C. A. Britton
Journal: JAMA (1986)

<h3>History</h3> A 34-year-old woman was admitted to the hospital with watery diarrhea, pain in the left lower quadrant, and persistent cough. A mild anemia and a leukocytosis with slight shift to the left were the only accompanying abnormal laboratory results. Further history is withheld. A barium enema examination (Fig 1) and a barium esophagram of the upper gastrointestinal tract (Fig 2) were performed. <h3>Diagnosis</h3> Crohn's disease involving the colon with esophageal involvement producing a tracheoesophageal fistula. <h3>Comment</h3> At age 24 years, this woman was first diagnosed as having Crohn's disease after developing rectal fistulas and oral ulcerations, both of which resolved with prednisone and sulfasalazine therapy. Five years later, she complained of cough, dysphagia, and watery diarrhea. Endoscopy revealed erythematous, friable mucosa in the midesophagus, which on biopsy was consistent with Crohn's disease. An increase in the intake of steroids resolved the patient's symptoms. She remained symptom free for five
Manuscripts Approved for JNCI, September 1 to October 1, 1970
Journal: JNCI Journal of the National Cancer Institute (1970)

Journal Article Manuscripts Approved for JNCI, September 1 to October 1, 1970 Get access JNCI: Journal of the National Cancer Institute, Volume 45, Issue 5, November 1970, Pages 1069–1070, https://doi.org/10.1093/jnci/45.5.1069 Published: 01 November 1970
Evaluating Health Risks from Occupational Exposure to Pesticides and the Regulatory Response
Authors: Tracey J. Woodruff, Amy D. Kyle, Frederic Y. Bois
Journal: Environmental Health Perspectives (1994)

In this study, we used measurements of occupational exposures to pesticides in agriculture to evaluate health risks and analyzed how the federal regulatory program is addressing these risks. Dose estimates developed by the State of California from measured occupational exposures to 41 pesticides were compared to standard indices of acute toxicity (LD50) and chronic effects (reference dose). Lifetime cancer risks were estimated using cancer potencies. Estimated absorbed daily doses for mixers, loaders, and applicators of pesticides ranged from less than 0.0001% to 48% of the estimated human LD50 values, and doses for 10 of 40 pesticides exceeded 1% of the estimated human LD50 values. Estimated lifetime absorbed daily doses ranged from 0.1% to 114,000% of the reference doses developed by the U.S. Environmental Protection Agency, and doses for 13 of 25 pesticides were above them. Lifetime cancer risks ranged from 1 per million to 1700 per million, and estimates for 12 of 13 pesticides were above 1 per million. Similar results were obtained for field workers and flaggers. For the pesticides examined, exposures pose greater risks of chronic effects than acute effects. Exposure reduction measures, including use of closed mixing systems and personal protective equipment, significantly reduced exposures. Proposed regulations rely primarily on requirements for personal protective equipment and use restrictions to protect workers. Chronic health risks are not considered in setting these requirements. Reviews of pesticides by the federal pesticide regulatory program have had little effect on occupational risks. Policy strategies that offer immediate protection for workers and that are not dependent on extensive review of individual pesticides should be pursued.
Impotence
Authors: R J Krane, I Goldstein, I Saenz de Tejada
Journal: New England Journal of Medicine (1989)

IMPOTENCE is a common disorder that in many people has a profound effect on their well-being. Recently, the field of erectile dysfunction has undergone considerable change. There is now an improved understanding of the physiologic mechanisms of penile erection and how these can be altered to cause impotence. New diagnostic tests make possible the recognition of specific causes of erectile dysfunction. Treatments such as intracavernosal injection of vasoactive agents by patients, vascular reconstructive surgery, and vacuum erection devices have been added to the options of hormonal therapy, psychological counseling, and penile implants. In this article we will review the progress . . .
Abstract 1127: Natural-Killer T Cells are Involved in the Development of Glucose Intolerance and Microalbuminuria in Diet-Induced Obese Mice
Authors: Kazue Ohmura, Naoki Ishimori, Yoshinori Ohmura, Satoshi Fujii, Yasuhiro Andoh, Hiroyuki Tsutsui
Journal: Circulation (2007)

Introduction: Natural killer T (NKT) cells are a unique subset of T lymphocytes, which recognize glycolipids and integrate inflammation producing pro-inflammatory cytokines on activation. We have demonstrated that NKT cells are present in atherosclerotic lesions and play a pivotal role in atherogenesis. NKT cells also reside in visceral adipose tissues, however, their pathogenic role has not been studied in metabolic derangements. Methods and Results: To determine whether NKT cells are involved in the development of metabolic phenotypes, male β 2 microglobulin knockout (KO) mice, which lack T cells and NKT cells, and C57BL/6J (WT) mice were fed an western diet (WD) containing 21% fat and 0.15% cholesterol or a chow diet for 13 weeks. In both KO (n=14) and WT (n=10) mice fed WD, visceral adipose-tissue weight, adipose cell size, and plasma leptin and non-HDL cholesterol levels were significantly increased compared to those fed a chow ( p&lt; 0.05) but did not differ between KO and WT mice. However, in KO mice fed WD, impaired glucose tolerance (plasma glucose 15 minutes after intraperitoneal glucose injection, 228±7 vs 343±31 mg/dl, p&lt; 0.001) and microalbuminuria (urine albumin/creatinin ratio, 10±1 vs 24±2 μg/mg, p&lt; 0.0001) were significantly ameliorated, but not in WT mice. Plasma TNF-α was significantly lower in KO mice than in WT mice (29±6 vs 85±40 pg/ml, p&lt; 0.05). Immunohistochemical staining of visceral adipose tissues revealed that F4/80 (+) macrophages in KO mice were markedly reduced to 34% of those in WT mice ( p&lt; 0.0001). To further confirm that NKT cells can aggravate metabolic derangements, WT mice received α-galactosylceramide (0.1μg/g), which specifically activates NKT cells, (αgC, n=5) or saline (PBS, n=5) injection after 13 weeks of feeding WD. In αgC mice, impaired glucose tolerance (347±9 vs 308±13 mg/dl, p&lt; 0.05) and microalbuminuria (35±8 vs 17±1 μg/mg, p&lt; 0.05) were significantly exacerbated as compared to PBS mice. Conclusions: NKT cells enhance chronic inflammation in visceral adipose tissues and contribute to the development of metabolic derangements in diet-induced obese mice. NKT cells may be novel therapeutic targets in the prevention of metabolic syndrome.
Vespers
Authors: Fred Coe
Journal: Annals of Internal Medicine (1992)

Ad Libitum1 October 1992VespersFred Coe, MDFred Coe, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-117-7-615_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptCome, night, at morning skilled hands cut this wrist,Alter channels that blood once racing pure,Now unclean, in arterial floods enterVeins, pound, stretch them, thicken walls that bulge, twistTo ripe blood sausages needle points burst,Let quick blood run out, be laved, return pure,Reeking of machine. Manacle, sign, scar,Pain's badge, my mark unto the final rest,Let me hide from you in one last sweet dream,Remember fingers petaled on this stalkRinged in amulets, cuffed in Venice lace,Held high in dance to catch a candle's gleam;My love, take my hand now in... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Chicago, IL 60637 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1992Volume 117, Issue 7Page: 615-615KeywordsBloodScarsVeins ePublished: 1 December 2008 Issue Published: 1 October 1992 PDF downloadLoading ...
Pharmacokinetics and Pharmacodynamics of Medroxyprogesterone Acetate in Advanced Breast Cancer Patients
Authors: M.C. Etienne, G. Milano, M. Frenay, N. Renee, E. Francois, A. Thyss, M. Schneider, M. Namer
Journal: Journal of Clinical Oncology (1992)

There were several production errors in the report by Etienne et al, "Pharmacokinetics and Pharmacodynamics of Medroxyprogesterone Acetate in Advanced Breast Cancer Patients," published in the July 1992 issue (J Clin Oncol 10:1176–1182, 1992). In the abstract (p 1176), the abbreviation "Css minutes" should have been "Css min" for minimum steady-state concentration. The P value for the second footnote to Table 2 (p 1178) should have been ".99." In the Discussion section, the fourth sentence of the second paragraph (p 1180) should have read: "As concerns the 70 patients who received 1,000 mg/d orally, MPA concentrations ranged from 10 to 269 ng/mL (Fig 1)."
Radiotherapy of advanced Hodgkin's disease with curative intent
Authors: H. S. Kaplan
Journal: JAMA (1973)

When the anatomical distribution and clinical stage of Hodgkin's disease have been established, rational decisions concerning the treatment of choice can be made. The initial therapeutic decision is crucial since the first course of treatment undoubtedly has the greatest chance of success. Depending upon circumstances, the physician must select one of three therapeutic options: (1) treatment with curative intent; (2) treatment with palliative intent; and (3) continued observation with general supportive care, with specific therapy held in reserve. The clinical stage of the disease is undoubtedly the most important factor influencing the selection of treatment. Only a decade ago, treatment with curative intent would have been deemed appropriate only for stage I disease, and for cases of localized, favorable stage II disease. Modern megavoltage apparatus has made possible the successful use of total lymphoid radiotherapy in cases of stage III and localized Rye stage IV<sup>10</sup>(Ann Arbor stage II
INFECTION DUE TO CHROMOBACTERIA
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gloucestershire cobalt unit.
Journal: BMJ (1967)

consultant radiotherapist for North Gloucestershire, together with several other con- sultants, invited a leading businessman in the Cheltenham area, Mr. Alexander Mills, to lead a local appeal.The aim of the appeal was to raise funds to buy a cobalt radiotherapy unit to treat patients with cancer.A small committee to plan the appeal campaign was set up in October, and in the following March the appeal was publicly launched.Within a year it had raised £88,000 from local people.Building started in July 1965, and in September 1966 a completely equipped new radiotherapy centre, with the cobalt unit, was officially opened.It is now in operation, serving the people who paid for it.This in a nutshell is the story of the North Gloucestershire Cobalt Unit Appeal.This spectacularly successful self-help campaign was organized by the people of North Gloucestershire and South Worcestershire to augment the local hospital service.The success of the campaign was due not to chance or unusual good fortune but to the organizers' unlimited enthusiasm and good planning, which was able to elicit the greatest response from the local people.
Nouveau traité de médecine.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
Authors: Ahmed Omar Kaseb, Roberto Carmagnani Pestana, Luis M. Vence, Jorge M. Blando, Shalini Singh, Naruhiko Ikoma, Kanwal Pratap Singh Raghav, Divya Sakamuri, Lauren Girard, Dongfeng Tan, Jean-Nicolas Vauthey, Ching-Wei David Tzeng, Thomas A. Aloia, Yun Shin Chun, James C. Yao, Robert A. Wolff, James Patrick Allison, Padmanee Sharma
Journal: Journal of Clinical Oncology (2019)

4098 Background: In HCC, surgical resection is associated with high recurrence rate, and no effective neoadjuvant or adjuvant therapies currently exist. On the basis of of previous reports on the efficacy and safety of anti–PD-1 (nivolumab) and anti–CTLA-4 (ipilimumab) antibodies against HCC, we initiated a randomized pilot trial of perioperative immunotherapy for resectable HCC. Methods: This is a randomized, phase II pilot trial of nivolumab (Arm A) or nivolumab + ipilimumab (Arm B) as pre-operative treatment for patients (pt) with HCC who are eligible for surgical resection. Pt are given nivolumab 240 mg every 2 weeks (wk) for a total of 6 wk. Pt in Arm B are treated concurrently with ipilimumab 1 mg/kg every 6 wk. Surgical resection occurs within 4 weeks after last cycle of therapy. Pt continue adjuvant immunotherapy for up to 2 years after resection. Primary objective is the safety and tolerability of nivolumab +/- ipilimumab. Secondary objectives include overall response rate, complete response rate and time to progression. Exploratory objectives include evaluating the pre- and post-treatment immunological changes in tumor tissues and peripheral blood. Results: 17 pt were enrolled at the time of interim analysis (8 in Arm A, 9 in Arm B) and 14 were evaluable. Most pt (53%) were 60-70yo, and males (70%). 6 pt were HCV-positive and 4 had chronic hepatitis B. 14 pt proceeded with resection as planned; surgery was aborted for 2 pt (1 for frozen abdomen and 1 for development of contralateral liver nodule). One is still receiving preoperative therapy. Pathologic complete response (pCR) was observed in 4/14 evaluable pt – 2 in Arm A and 2 Arm B (29% pCR rate). 4 pt in Arm B and 1 in Arm A experienced grade 3 or higher toxicity prior to surgery. Conclusions: We report a pCR rate of 29% in an interim analysis of a phase II pilot trial of perioperative immunotherapy for resectable HCC. Treatment was safe and surgical resection was not delayed. The study is ongoing and results may contribute to a paradigm shift in the perioperative treatment of HCC. Clinical trial information: NCT03222076.
A study of the XYY syndrome in tall men and juvenile delinquents
Authors: M. J. Marinello
Journal: JAMA (1969)

Four new examples of the XYY karyotype were ascertained in a survey of selected male populations. Among men 183 cm (6 ft) or greater in height, two out of 86 tested in a state prison, one out of 76 tested in a mental hospital, and none in 30 normal men were found to be XYY. One 11-year-old boy was also found among a group of 57 male juvenile offenders not selected for height, referred from a family court clinic. None of the XYY subjects showed significant physical abnormalities other than increased height. All came from broken or unsatisfactory homes, perhaps an important factor in leading to their sociopathic behavior.
受监护的身体锻炼作为下肢静脉溃疡的替代疗法:随机对照可行性试验
Authors: M. Klonizakis, G.A. Tew, A. Gumber, H. Crank, B. King, G. Middleton, J.A. Michaels
Journal: British Journal of Dermatology (2018)

下肢静脉溃疡(伤口)会因为下肢血管阻塞或损坏而引起。使用绷带或袜子进行压迫有助于治愈溃疡,但效果并不稳定。静脉溃疡患者通常会受到鼓励去锻炼身体,但是有关体育锻炼对该人群是否有效和安全的信息却很少。因此,本研究尝试让使用压迫法治疗下肢静脉溃疡的英国患者在有人监护下进行体育锻炼。参与者经过随机分配,接受常规护理,或者常规护理加12周的受监护锻炼计划。锻炼计划每周三次,每次锻炼结合步行、骑单车以及针对腿部肌肉力量和灵活性的锻炼项目。对患者进行长达一年的追踪,收集了有关溃疡治愈、生活质量和就医情况(例如GP就诊)的数据。研究共招募了三十九人,其中18人被分配到锻炼组。仅有两名参与者未完成研究。总体锻炼出勤率为79%,13名参与者(72%)完成所有锻炼项目。未出现严重的不良事件(不良副作用)。锻炼组的平均溃疡治愈时间较短:13周对比35周。这些发现验证了受监护的体育锻炼对使用压迫法治疗下肢静脉溃疡患者的可行性。需要更大规模的研究确认对溃疡愈合的效果以及锻炼是否具有成本效益。
Violation of State Pharmacy Act.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DR. YERSIN, THE DISCOVERER OF THE ANTI-PLAGUE SERUM.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AMA initiative on quality of medical care and professional self-regulation
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal